Sean Pittock, EAN 2020 – Phase 3 PREVENT Study Insights in Neuromyelitis Optica Spectrum Disorder

Sean Pittock (Mayo Clinic College of Medicine, Rochester, MN, USA) shared with us his expert insights from the phase 3 PREVENT study, a randomized controlled trial of eculizumab in AQP4 antibody-positive participants with neuromyelitis optica (ClinicalTrials.gov Identifier: NCT01892345), including a sub analysis he presented on eculizumab monotherapy.

Questions
1. Could you give us an overview of neuromyelitis optica spectrum disorder (NMOSD), its pathophysiology and manifestations? (0:05)
2. What are the unmet needs in the treatment of NMOSD? (1:12)
3. What is the rationale for the use of eculizumab in the treatment of NMOSD? (2:23)
4. Could you tell us a little about the aims and design of the PREVENT study? (3:47)
5. What have been the major efficacy and safety findings of the study? (4:56)
6. What can you tell us about eculizumab monotherapy in NMOSD based on the PREVENT subgroup analysis you presented as an ePoster in the late-breaking session at EAN 2020? (6:20)

Speaker disclosure: Sean Pittock reports grants from Grifols, other from Euroimmun, grants from NIH, grants, personal fees and non-financial support from Guthy Jackson Charitable Foundation, grants from AEA (Autoimmune Encephalitis Alliance), grants, personal fees, non-financial support and other from MedImmune, Inc., other from Astellas, personal fees from UCB, Inc., personal fees from Hoffman/LaRoche AG, grants, personal fees, non-financial support and other from Alexion Pharmaceuticals, Inc., outside the submitted work; In addition, Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) – Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, a patent Patent# 9,891,219B2 (Application#12-573942) – Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued, a patent GFAP-IgG pending, a patent Septin-5-IgG pending, a patent MAP1B-IgG pending, a patent Kelch-like protein 11 pending, and a patent PDE10A pending.

Support: Interview and filming supported by Touch Medical Media.

Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.